David Jacobs, MD
Ophthalmology · Richmond, VANPI 1184675100
Payments from drug & device makers
Across 299 payments — averaging $54.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Notal Vision, Inc.$7K
- Genentech, Inc.$7K
- AbbVie$969
- Halozyme Inc$380
- Genentech USA, Inc.$362
- Alimera Sciences, Inc.$326
- plus $1K from 11 others
What the payments were for
- Speaking & faculty fees$38110%
- Food & beverage$3,43290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Notal Vision, Inc. | 169 | $6,674 |
| Genentech, Inc. | 3 | $6,660 |
| AbbVie(2 entities) | 68 | $969 |
| Halozyme Inc | 1 | $380 |
| Genentech USA, Inc. | 12 | $362 |
| Alimera Sciences, Inc. | 7 | $326 |
| Regeneron Healthcare Solutions, Inc. | 11 | $284 |
| Mallinckrodt Hospital Products Inc. | 6 | $180 |
| Apellis Pharmaceuticals, Inc. | 2 | $148 |
| Astellas Pharma US Inc | 4 | $112 |
| Bausch & Lomb Americas Inc. | 5 | $90 |
| Alcon | 4 | $70 |
| Harrow Eye, LLC | 2 | $38 |
| ANI Pharmaceuticals, Inc. | 2 | $36 |
| Eyepoint US, Inc. | 1 | $19 |
| Carl Zeiss Meditec USA, Inc. | 1 | $18 |
| Novartis | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HYLENEX RECOMBINANT$380
- VABYSMO$336
- OZURDEX$244
- Syfovre$125
- Iluvien$123
How this compares
$16,383 in reported general payments places this provider in the 90th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 243 | $9,926 |
| Bromfenac Sodium | 28 | $4,612 |
| Difluprednate | 33 | $3,645 |
| Atropine Sulfate | 124 | $3,032 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 103 | $1,797 |
| Ketorolac Tromethamine | 51 | $1,374 |
| Latanoprost | 145 | $975 |
| Ofloxacin | 87 | $873 |
| Timolol Maleate | 57 | $328 |
| Brimonidine Tartrate | 19 | $108 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Richmond
- Ali TabassianRichmond$2.1M
- Ethnie JonesRichmond$2M
- John O KeefeRichmond$44K
- Byron LaddRichmond$32K
- Thomas JenkinsRichmond$26K
- Ryan DeasyRichmond$19K
- Jessica RandolphRichmond$18K
- Nikisha RichardsRichmond$16K
- Kenneth PriceRichmond$14K
- Tam DangRichmond$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.